Bexion Pharmaceuticals, Inc. Represented at 15 th Annual BioNetwork Partnering Summit
National Cancer Institute (NCI) S elects Bexion as a Presenting Company FOR IMMEDIATE RELEASE Covington, KY ~ October 1 8 , 201 8 - Bexion Pharmaceuticals, Inc., a clini cal stage biotechnology company focused on developing [...]
Patient No. 1 and the cancer trial here that just might change everything
Cincinnati Enquirer (Aug. 8, 2018) If you saw Bob Rulli on the street, you’d never guess he had cancer. He's the first person to receive a first-of-its-kind drug made in Cincinnati. (Photo: Kareem Elgazzar/The Enquirer) [...]
Bexion Pharmaceuticals, Inc. Announces Grant from CancerFree KIDS
CancerFree KIDS Awards Nationwide Children’s Hospital Monies to Initiate Pediatric Trial FOR IMMEDIATE RELEASE Covington, KY, June 19, 2018 - Sometimes things come full circle. Fourteen years ago , CancerFree KIDS awarded its very first [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
Clinical Trials
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857